Asthma - Drug Pipeline Landscape, 2022

Asthma - Drug Pipeline Landscape, 2022

Asthma is a chronic inflammatory disease of the lungs. The airways in the lungs become narrow due to inflammation and tightening of the muscles around the small airways and also due to excess mucus. It is characterised by airflow obstruction and triggers bronchospasms.

Signs and symptoms of asthma includes shortness of breath, chest tightness, recurrent episodes of wheezing and cough. These symptoms vary from person to person. The symptoms get worse during night or with exercise.

Asthma is caused by a combination of environmental and genetic interactions. Allergies can raise the development of asthma, certain respiratory infections such as RSV can affect children. Exposure to tobacco smoke and other sources of air pollution can increase the risk.

There is currently no precise test for the diagnosis, which is typically based on the pattern of symptoms and response to therapy over time. The condition is suspected with a history of recurrent wheezing, coughing or difficulty breathing. The main tests include spirometry, peak flow test and FeNO test.

Asthma treatment aims in reducing the inflammation and bronchoconstriction of the airways. This involves the anti-inflammatory agents for the mildest symptoms.  Other medications involve, bronchodilators, anticholinergics, corticosteroids and biologics. Avoidance of triggers is a key component of improving control and preventing attacks.

Report Highlights

Global Insight Service’s, Asthma - Drug Pipeline Landscape, 2022 report provides an overview of the Asthma pipeline drugs. This report covers detailed insights on Asthma drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Asthma pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy

Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.

Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.

Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.

Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.